315 studies found for:    gefitinib
Show Display Options
Rank Status Study
1 Completed Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: Gefitinib
2 Completed
Has Results
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gefitinib retreatment
3 Completed
Has Results
Gefitinib (Iressa) and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Gefitinib;   Radiation: Local Irradiation
4 Completed Phase III Randomized, Placebo Controlled, Trial Of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib, NSC 715055) In Performance Status 2 Or Previously Treated Patients With Recurrent Or Metastatic Head And Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel;   Other: placebo;   Drug: gefitinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib, Hydroxychloroquine
6 Unknown  Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib and Nimotuzumab;   Drug: Gefitinib
7 Completed
Has Results
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Gefitinib + Sunitinib
8 Completed High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Gefitinib
9 Completed ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Condition: Skin Cancer
Intervention: Drug: Iressa
10 Completed Gefitinib in Treating Children With Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gefitinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Terminated Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Condition: BREAST CANCER
Interventions: Drug: Iressa Day 1 given with Arimidex and Faslodex;   Drug: Iressa Day 21 given with Arimidex and Faslodex
12 Recruiting Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Gefitinib plus olaparib
13 Completed Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Interventions: Drug: simvastatin;   Drug: gefitinib only
14 Completed Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: gefitinib;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
15 Active, not recruiting Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: Topotecan;   Drug: Gefitinib
16 Completed
Has Results
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib;   Drug: Placebo
17 Active, not recruiting Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: ZD1839 (Iressa)
18 Terminated Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Condition: Esophageal Cancer
Interventions: Drug: cisplatin;   Drug: gefitinib;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: adjuvant therapy;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
19 Completed Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib 500mg/Gefitinib 250mg
20 Completed A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: celecoxib, gefitinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years